Entrada Therapeutics, Inc. (TRDA-Q)
NASDAQ:TRDA
8.38
0.24
(2.78%) 1d
Financials
Technical Analysis
Buy, Sell or Hold?
Related posts
Nervous markets await Nvidia
This summary was created by AI, based on 3 opinions in the last 12 months.
Entrada Therapeutics, Inc. (TRDA-Q) has received mixed reviews from Stockchase Research Editor Michael O'Reilly, with past recommendations showcasing strong performance and strategic adjustments. The company has managed to trigger a stop loss recently at $16, resulting in a net investment gain of 12% for investors. Most recently, TRDA reached its target at $21, prompting a recommendation to cover half the position while trailing the stop-loss to $16. Furthermore, the company's fundamentals appear solid, with a low trailing earnings multiple, significant return on equity, and growing cash reserves supporting its drug portfolio, which focuses on delivering RNA-based therapeutics. The experts suggest a cautious yet optimistic outlook for TRDA, indicating an upside potential with strategic management of positions.
This pharma company produces clinical stage drugs that aid the delivery of other therapeutics and they have been advancing a portfolio of RNA based programs. It trades at 6x trailing earnings, under 1.5x book and supports a 32% ROE and has growing cash reserves. We recommend setting a stop-loss at $13, looking to achieve $21 -- upside potential of 27%. Yield 0%
(Analysts’ price target is $21.50)- «
- ‹
- 1
- ›
- »
Entrada Therapeutics, Inc.(TRDA-Q) Rating
Ranking : 4 out of 5
Bullish - Buy Signals / Votes : 2
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 0
Total Signals / Votes : 2
Entrada Therapeutics, Inc.(TRDA-Q) Frequently Asked Questions
What is Entrada Therapeutics, Inc. stock symbol?
Entrada Therapeutics, Inc. is a American stock, trading under the symbol TRDA-Q on the NASDAQ (TRDA). It is usually referred to as NASDAQ:TRDA or TRDA-Q
Is Entrada Therapeutics, Inc. a buy or a sell?
In the last year, 2 stock analysts published opinions about TRDA-Q. 2 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Entrada Therapeutics, Inc..
Is Entrada Therapeutics, Inc. a good investment or a top pick?
Entrada Therapeutics, Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Entrada Therapeutics, Inc..
Why is Entrada Therapeutics, Inc. stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Entrada Therapeutics, Inc. worth watching?
In the last year, there was no coverage of Entrada Therapeutics, Inc. published on Stockchase.
What is Entrada Therapeutics, Inc. stock price?
On 2025-05-09, Entrada Therapeutics, Inc. (TRDA-Q) stock closed at a price of $8.38.
Our PAST TOP PICK with TRDA has triggered its stop at $16. To remain disciplined, we recommend covering the position at this time. This will result in a net investment gain of 12%, when combined with our previous guidance.